VBI Vaccines (NASDAQ:VBIV) Third Quarter 2023 Results

Key Financial Results

• Revenue: US$6.62m (up by US$6.31m from 3Q 2022).
• Net loss: US$21.3m (loss narrowed by 16% from 3Q 2022).
• US$1.01 loss per share (improved from US$2.93 loss in 3Q 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

VBI Vaccines Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 50%. Earnings per share (EPS) also missed analyst estimates significantly.

Looking ahead, revenue is forecast to grow 51% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 1.2% from a week ago.

Risk Analysis

It is worth noting though that we have found 5 warning signs for VBI Vaccines (1 is concerning!) that you need to take into consideration.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.